CLINICAL TRIALS PROFILE FOR AXIRON
✉ Email this page to a colleague
All Clinical Trials for Axiron
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00702650 ↗ | A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations | Completed | Eli Lilly and Company | Phase 3 | 2008-06-01 | Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product- Testosterone MD-Lotion (cutaneous solution), and this study will evaluate the efficacy via pharmacokinetics of various doses of this product. The study will also assess safety of the product. |
| NCT00857454 ↗ | A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations | Completed | Eli Lilly and Company | Phase 3 | 2008-10-01 | Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone MD-Lotion® (cutaneous solution) after completion of the MTE08 (NCT00702650) trial. |
| NCT00857961 ↗ | A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations | Completed | Eli Lilly and Company | Phase 2 | 2007-10-01 | Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will evaluate pharmacokinetics of testosterone MD-Lotion formulations.The study will also assess safety of the product. |
| NCT01419236 ↗ | A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels | Completed | Eli Lilly and Company | Phase 2 | 2011-08-01 | The purpose of this study is to see if testosterone solution 2% can impact symptoms of ejaculatory dysfunction in men with low testosterone. |
| NCT01725451 ↗ | A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | 2012-11-01 | This study will evaluate the effect of deodorant and antiperspirant use and the presence of underarm hair on the absorption of testosterone. Each participant in this study will receive 6 single doses of 30 milligrams (mg) testosterone applied as a solution to each underarm. There is a minimum one day washout period between each dose. This study will last approximately 24 days not including screening. Screening is required within 30 days prior to the start of the study. |
| NCT01816295 ↗ | A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy | Completed | Eli Lilly and Company | Phase 3 | 2013-05-01 | The main purpose of this study is to evaluate if testosterone solution can raise testosterone hormone levels into the normal range, and also improve levels of sexual arousal, interest and drive and/or energy level, in men with low testosterone and decreased sexual arousal, interest and drive and/or decreased energy. The study will last about 16 weeks, followed by an optional 24 week open label treatment phase to investigate the long term safety of testosterone solution. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Axiron
Condition Name
Clinical Trial Locations for Axiron
Trials by Country
Clinical Trial Progress for Axiron
Clinical Trial Phase
Clinical Trial Sponsors for Axiron
Sponsor Name
